2021
Identification and Validation of Distinct Latent Neurodevelopmental Profiles in the Adolescent Brain and Cognitive Development Study
Lichenstein SD, Roos C, Kohler R, Kiluk B, Carroll KM, Worhunsky PD, Witkiewitz K, Yip SW. Identification and Validation of Distinct Latent Neurodevelopmental Profiles in the Adolescent Brain and Cognitive Development Study. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2021, 7: 352-361. PMID: 33706021, PMCID: PMC8426420, DOI: 10.1016/j.bpsc.2021.02.013.Peer-Reviewed Original ResearchConceptsAdolescent brainHigher emotion regulationCognitive Development StudyDevelopment of psychopathologyFunctional magnetic resonanceLow-reward groupLatent profile analysisEmotion regulationCognitive performanceDevelopmental subgroupsNeurodevelopmental profileSubgroup of individualsHigh rewardReward groupIdentified subgroupsNeurodevelopmental modelModerate groupNeurodevelopmental disordersPsychiatric riskMore screen timeCurrent studyDevelopmental profileNeural functionDevelopment studiesScreen time
2013
Polypharmacy Reduction in Youth in a Residential Treatment Center Leads to Positive Treatment Outcomes and Significant Cost Savings
van Wattum PJ, Fabius C, Roos C, Smith C, Johnson T. Polypharmacy Reduction in Youth in a Residential Treatment Center Leads to Positive Treatment Outcomes and Significant Cost Savings. Journal Of Child And Adolescent Psychopharmacology 2013, 23: 620-627. PMID: 24251644, DOI: 10.1089/cap.2013.0014.Peer-Reviewed Original ResearchConceptsMedication reductionTreatment centersResidential treatment centerTreatment outcomesLong-term treatment outcomesUse of antipsychoticsNumber of antipsychoticsPlace of dischargePositive treatment outcomesAdmission medicationsAntipsychotic combinationsPolypharmacy reductionPostdischarge dataDischarge medicationsMore medicationsAvailable followMonths postdischargeMood stabilizersPolypharmacy regimensMedicationsAdmissionYouth ages 11Mean numberHealthcare systemAntipsychotics